Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 10/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721067 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL4592059 | 0.83 | TRPV3 (0.61) | TRPV3SCN9A | |
| SCHEMBL30755490 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL4831269 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL27371412 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4HCTSS | |
| SCHEMBL6484177 | 0.81 | SCN9A (0.43) | TRPV3SCN9A | |
| SCHEMBL4591287 | 0.80 | SCN5A (0.48) | TRPV3SCN9A | |
| SCHEMBL4592241 | 0.79 | GFER (0.47) | — | |
| SCHEMBL5376937 | 0.78 | MEN1 (0.60) | TRPV3 | |
| SCHEMBL8989216 | 0.77 | MEN1 (0.43) | TRPV3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101213186-A | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | TRPV3 920/4885SCN9A 1166/4885KIF11 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.